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Background: Until now the exact biochemical processes during healing of metaphyseal fractures of healthy and
osteoporotic bone remain unclear. Especially the physiological time courses of 25(OH)D3 (Vitamin D) as well as PTH
(Parathyroid Hormone) the most important modulators of calcium and bone homeostasis are not yet examined
sufficiently. The purpose of this study was to focus on the time course of these parameters during fracture healing.
Methods: In the presented study, we analyse the time course of 25(OH)D3 and PTH during fracture healing of low
BMD level fractures versus normal BMD level fractures in a matched pair analysis. Between March 2007 and
February 2009 30 patients older than 50 years of age who had suffered a metaphyseal fracture of the proximal
humerus, the distal radius or the proximal femur were included in our study. Osteoporosis was verified by DEXA
measuring. The time courses of 25(OH)D3 and PTH were examined over an eight week period. Friedmann test, the
Wilcoxon signed rank test and the Mann-Withney U test were used as post-hoc tests. A p-value ≤ 0.05 was
considered significant.
Results: Serum levels of 25(OH)D3 showed no differences in both groups. In the first phase of fracture healing PTH
levels in the low BMD level group remained below those of the normal BMD group in absolute figures. Over all no
significant differences between low BMD level bone and normal BMD level bone could be detected in our study.
Conclusions: The time course of 25(OH)D3 and PTH during fracture healing of patients with normal and low bone
mineral density were examined for the first time in humans in this setting and allowing molecular biological insights
into fracture healing in metaphyseal bones on a molecural level. There were no significant differences between
patients with normal and low BMD levels. Hence further studies will be necessary to obtain more detailed insight into
fracture healing in order to provide reliable decision criteria for therapy and the monitoring of fracture healing.Background
Low serum levels of 25(OH)D3 are suggested to be asso-
ciated with reduced BMD (bone mineral density) [1,2].
Lips et al. found reduced levels of serum 25(OH)D3 to
be common amongst women with osteoporosis [3]. The
diminishing ability of the skin to synthesize 25(OH)D3* Correspondence: cwoelfl@bgu-ludwigshafen.de
ˆDeceased
1Department of Trauma- and Orthopaedic Surgery, BG Trauma Centre
Ludwigshafen, Ludwig- Guttmann-Str.13, Ludwigshafen 67071, Germany
Full list of author information is available at the end of the article
© 2013 Wöfl et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
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sons [4,5].
Individuals with vitamin D deficiency are more likely
to fall and to lose muscle mass [6]. Chronic insufficiency
of 25(OH)D3 leads to secondary hyperparathyroidism
with increased bone turnover, bone loss and thus a
higher fracture risk [4]. As a result, guidelines for the
management of postmenopausal osteoporosis typically
include recommendations for its supplementation [7,8].
During fracture repair, circulating levels of 25(OH) D3 in-
crease in white leghorn chickens due to an increase ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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degrades 1.25-(OH)2D to calcitroic acid) [9]. Serum 1.25-
(OH)2D levels after sustaining a fracture have only been
measured in a few studies with humans [10]. Significantly
reduced levels were found 28 hours after sustaining the
fracture.
There are only few studies, observing the time course
of 25(OH)D3 during the fracture healing, neither in
healthy nor in osteoporotic bone. Meller et al. investi-
gated on it and amongst others also on PTH in a popu-
lation of 13 young adult patients without osteoporosis
and long bone fractures [11] and in a population of 41
geriatric patients with proximal femur fractures [12].
The second major mediator of bone remodelling is the
parathyroid hormone (PTH). PTH regulates serum cal-
cium levels by acting mainly on bones and kidneys. Two
important functions e.g. are stimulating of renal calcium
re-absorption and bone resorbtion when calcium levels
are low [13]. The intermittent administration of human
parathyroid hormone is to date the only clinically approved
bone anabolic therapy for osteoporotic patients of both
genders [14].
The 84-amino-acid polypeptide hormone is an essen-
tial regulator of calcium homeostasis [15]. PTH and
PTHrP (PTH-related protein) indirectly activate osteo-
clasts leading to increased bone resorption [16]. The
hypercalcemic effect of PTH lies, in part, in its effect on
the nephron enhancing renal calcium reabsorption and,
in part, in bone resorption [17].
PTH infused continuously reduces BMD, increases
levels of bone resorption marker TRAP-5b and raises
serum calcium levels [17,18]. An intermittent application
of PTH that permits complete serum clearence between
doses [19] increases 1.25-(OH)2D and BMD, raises levels
of bone formation marker osteocalcin without producing
hypocalcaemia. 1.25-(OH)2D complements this PTH ef-
fect and may therefore facilitate an optimal skeletal re-
sponse to PTH. This indicates that a full response
requires an active 1.25-(OH)2D synthesizing system [17].
Some clinical studies indicate that a daily subcutane-
ous injection of PTH stimulates the development of new
bone, increases bone mass in patients with osteoporosis
[20] and reduces the incidence of fractures in postmeno-
pausal women [21].
Administered during fracture healing PTH promotes
bone healing in healthy and osteoporotic rats, when it is
applied during early stage of healing without having any
adverse systemic effect [22].
So far there is no data on the endogenic behaviour of
PTH during fracture repair of healthy or osteoporotic
bones. In our study, we therefore examined the time
courses of 25(OH)D3 and PTH during healing of meta-
physeal fractures of normal and low BMD level long
bones.Methods
Between March 2007 and February 2009 all patients
over 50 years of age who had suffered a metaphyseal
fracture (distal radius-, proximal humerus- and proximal
femur fracture) with an obligatory indication for surgical
stabilization were included in this study. Exclusion cri-
teria were defined as: polytrauma, significant soft tissue
injury, high grade open fracture, > 24h mechanical venti-
lation after surgery, dialysis patients, long-term therapy
with immunosuppressants such as corticosteroids, col-
lagenosis, chronic inflammatory bowel disease, haemato-
logical disorders, malignant neoplasms and metabolic
bone diseases (osteomalcia, hyperparathyreodism, Paget’s
disease).
In all patients X-rays of the fractured region and also
of the lumbar spine were performed in an anterior-
posterior and lateral view. X-rays of the lumbar spine
were used to exclude morphological changes of the ver-
tebrae leading to wrong values in DXA bone density
measurements. To monitor the clinical course of frac-
ture healing, follow-up X-rays of the fractured site were
performed after 4 and 8 weeks, and also one year after
osteosynthetic stabilization.
BMD was examined on the lumbar spine, the entire hip
on both sides and the hip subregions using dual energy
X-ray absorptiometry DXA (Lunar iDPX, GE Medical Sys-
tems Germany, Solingen, Germany) based on Encore TM
Version II.X software. One year after surgery follow-up
DXA measurements were performed. Using normative
data for young adult white people, BMD was categorized
as normal, low bone mineral density, or osteoporosis, as
defined by the World Health Organization. Participants
with a T-score ≤ −2.5 SD were categorized as having
osteoporosis.
Laboratory analysis was performed the morning after
injury in fasting state. Among typical routine laboratory
values, 25(OH)D3 and parathyroid hormone PTH were
examined. Quantitative measurement was detected using
chemiluminescence immunoassay “Access Ostase assay
37300” (Beckman Coulter™, Brea, USA) and electroche-
miluminescence immunoassay ECLIAW (Roche, Basel,
Switzerland). The laboratory values were followed-up
one, four and eight weeks after suregry. The following
kits where used:
Vitamin D3/25(OH)D3:
cobasW 25 Hydroxyvitamin D3 03314847 190, Roche
Diagnostics GmbH, D-68298 Mannheim
PTH (Draft):
cobasW Parathyroid hormone – PTH, intact 11972103
160, Roche Diagnostics GmbH, D-68298 Mannheim
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porosis medication in this period.
The study was designed as an epidemiological case–
control study. After receiving the results from DXA-
measuring, patients were matched in osteoporotic and
nonosteoporotic groups. Further matching-criteria were:
age (+/- 5 years), sex (male, female), fracture localization
(proximal humerus, distal radius, proximal femur), frac-
ture type (according to AO-classification; A-, B- or C-
type fractures) and surgical technique (plate, intramedular
nail). Thus we received a collective of 15 matched pairs
(30 patients in total).
Statistics were performed using the software SPSS
11.0.0 (IBM Germany, Munich, Germany) and Microsoft
Excel 2003/2007, Microsoft Corp. Washington, USA. By
Pretrail-Power analysis of the first three patients we cal-
culated that 15 matched pairs would be necessary to
achieve statistical significance. To show comparisons
over the time within one group, we first performed
Friedman’s test. As post-hoc test we then performed
Wilcoxon-test. We performed Wilcoxon’s rank-sum test
in addition to compare both groups at one point in time.
P ≤ 0.05 was considered to be significant.
Results
Between March 2007 and February 2009 54 patients over
50 years of age who had suffered a metaphyseal fracture of
the proximal humerus, the distal radius or the proximal
femur were included in our study. In total 15 matched
pairs were constructed according to the presented match-
ing criteria (Table 1) and their base line demographic data
(Table 2). There were 7 pairs with fractures of the distal
radius, 3 pairs with proximal humeral fractures and 6 pairs
with proximal femoral fractures (including femoral neck
and intertrochanteric fractures).
The results of laboratory analyses of 25(OH)D3 and
PTH are presented graphically in Figures 1 and 2.
Serum values of 25(OH)D3 during fracture healing of
low BMD level patients and normal BMD level patients
show no significant differences.
The time course of PTH also showed no significant
changes in both groups. In the first phase of fracture
healing PTH of the low BMD level group stayed below
the level of the normal BMD level group.
Discussion
Vitamin D is transformed into its active hormonal con-
ditions through hydroxylation of hormone precursors,
e.g. into 25-hydroxyvitamin D in the liver and then into
1α, 25-dihydroxyvitamin D [1.25-(OH)2D] in the kid-
neys. This active hormonal state of vitamin D plays an
essential role in bone homeostasis. Upon reaching the
bones as one of its target tissue, several functions are
discussed. The leading effect of the vitamin D hormoneon bones is indirect and mediated through its endocrine
function on mineral homeostasis [23]. However, also
binding its receptor (vitamin D receptor or VDR) a
receptor-regulated pathway acts regulating transcription
of target genes responsible for conducting the physio-
logical process of 1.25-(OH)2D [24,25].
The physiological level of 25(OH)D3 still remains un-
clear and ranges from 12 ng/ml to 40 ng/ml mean
[3,22]. The observed mean level of 25(OH)D3 in our
study ranged from 16.3 ± 5.2 ng/ml to 18.3 ± 5.1 ng/ml
and is similar to mean values found with other authors,
describing the mean 14.7 ± 6.4 ng/ml [26].
Concerning fracture repair, the time course of 25(OH)
D3 was examined in chicks over periods of maximal 21
days. Increasing levels of 25(OH)D3 were observed in
the chicks due to an increase in CYP24A1 activity,
whereas serum calcium levels revealed the same. Expos-
ure of kidney cells in cultures to serum obtained from
chicks with fractures showed an increase in CYP24A1
activity compared to control serum. This suggests that
25(OH)D3 is involved in the early stages of fracture re-
pair and that there is some form of physiological com-
munication between the fractured bone and the kidneys
leading to an increase of renal 24-hydroxylase and the
circulating concentration of this metabolite [9].
In mice CYP24a1 mRNA levels were significantly ele-
vated in the fracture callus compared to the callus of the
undamaged contralateral bone [23] and in CYP24a1-/-
mice a delay in the mineralization of the cartilagous
matrix of the soft callus and an altered expression of dif-
ferentiation marker genes were found [23].
The presence of a nonnuclear membrane receptor for
25(OH)D3 in the fracture healing callus has been sug-
gested [27,28] as well as a receptor/binding protein for
25(OH)D3 in the fracture healing callus membrane frac-
tion from 25(OH)D3 depleted chicks [28].
Serum 25(OH)D3 levels after sustaining a fracture have
only been measured in few studies with humans [10-12].
Significantly reduced levels were found 28 hours after
sustaining the fracture.
There are two interesting studies from Meller et al. in
humans in 1982 and 1984 (11,12). In the first study,
regarding 25(OH)D3, 13 young adults who had sustained
fractures of a long bone, pelvis and vertebral bodies were
included. Blood samples were taken within 12 hours after
sustaining the fracture and also after six to eight weeks
(with the sign of primary callus). During the healing
period of the fractures no significant changes could be
detected in the selected two pints of time. In the second
study he investigated a population of 41 geriatric patients
with 43 fractures of the proximal femur. 31 fractures were
treated operatively while 12 non-operatively. Again blood
samples were taken at two points in time, i.e. 48 hours
after administration and after 8 weeks. Concerning the
Table 1 Table of matched pairs






BMI (kg/m2) Weight (kg) Height (cm) Creatinin
(mg/dl)
1 female 57 dist. radius fracture 23A3/AO plate -1.3 22.4 64 169 0.77
1 female 59 dist. radius fracture 23A3/AO plate -2.7 28.3 79 167 0.72
2 female 60 dist. radius fracture 23A3/AO plate -1.0 27.7 80 170 0.68
2 female 61 dist. radius fracture 23A3/AO plate -2.6 26.4 72 165 0.9
3 female 57 dist. radius fracture 23A3/AO plate -0.4 28.1 72 177 0.75
3 female 57 dist. radius fracture 23A3/AO plate -2.5 21.3 69 180 0.83
4 female 63 dist. radius fracture 23A3/AO plate 0.1 22.7 71 177 0.45
4 female 67 dist. radius fracture 23A3/AO plate -3.1 28 80 169 0.73
5 female 66 dist. radius fracture 23A3/AO plate 0.9 20.8 56 164 0.87
5 female 68 dist. radius fracture 23A3/AO plate -2.5 33.3 95 169 0.90
6 female 65 dist. radius fracture 23A3/AO plate -0.7 23.7 73.5 176 0.92
6 female 63 dist. radius fracture 23A3/AO plate -3.2 20.3 60 172 0.84
7 female 56 dist. radius fracture 23A3/AO plate -0.3 25.4 65 160 0.75
7 female 69 dist. radius fracture 23A3/AO plate -3.9 35.5 82 169 0.74
8 female 60 prox. hum. fracture 11A3/AO plate -1.9 40.6 136 183 0.68
8 female 59 prox. hum. fracture 11A3/AO plate -3.7 32.5 87 155 0.72
9 female 68 prox. hum. fracture 11C1/AO plate -0.4 20.9 70 183 0.66
9 female 71 prox. hum. fracture 11C1/AO plate -2.7 23.2 65 167 0.63
10 female 74 prox. hum. fracture 11C2/AO plate -1.0 33.3 75 150 1.1
10 female 78 prox. hum. fracture 11C2/AO plate -3.0 22 62 168 0.84
11 male 72 fem. neck fracture 31B1/AO screws 0.3 23.5 68 170 0.89
11 male 75 fem. neck fracture 31B1/AO screws -2.6 28.4 92 180 0.67
12 male 64 fem. neck fracture 31B1/AO DHS -0.2 25.4 65 160 0.73
12 male 68 fem. neck fracture 31B1/AO DHS -2.8 30.1 84 167 0.80
13 female 59 intertr. fracture 31A2/AO DHS -1.1 29.3 77 162 0.70
13 female 63 intertr. fracture 31A2/AO DHS -2.7 20.8 60 170 0.87
14 female 66 intertr. fracture 31A3/AO PFN 0.25 23.1 63 165 0.76
14 female 70 intertr. fracture 31A3/AO PFN -2.6 27.4 65 154 0.87
15 male 64 intertr. fracture 31A3/AO PFN -0.4 23.3 65 167 0.71
15 male 62 intertr. fracture 31A3/AO PFN -3.2 29.1 90 176 0.64
Matching criteria were age (+/- 5 years), sex (male, female), fracture localization (proximal humerus, distal radius, proximal femur), fracture type (according to
AO-classification; A-, B- or C-type fractures) and operation method (plate, intramedullary nail). T-Score, BMI, weight, height and creatinin.
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could be demonstrated.
Our study is the first study to examen the time course
of 25(OH)D3 during human fracture healing in normal
BMD level bone and low BMD level bone in a timeTable 2 Table of demographic data of the patientents showin
demographics
Mean
Parameter Normal BMD Low BMD
age 63.40 66.0
BMI (kg/m2) 26.01 27.11
weight (kg) 73.37 76.13
height (cm0 168.87 168.53
creatinin (mg/dl) 0.7613 0.78course with blood samples taken at four different points
in time. We could not confirm the increase of 25(OH)
D3 during the healing period, which we had expected,
but rather a slight decrease. This heterogeneity may be
explained by the different study designs, meaning resultsg no significant differences in their base line
Standard deviation p-values (T-Test)






Figure 1 25(OH)VitD3 – time course.
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Comparing our results with the studies of Meller, it only
remains for us to show these first results as a basis for
further investigations.
In addition, no significant differences could be detected
between the normal and low BMD level groups in our
study with regard to levels of 25(OH)D3. This contradicts
reports of low levels of 25(OH)D3 in osteoporotic patients
in the literature so far [1,29]. In fact, there are other
authors, who failed to show any significant correlation be-
tween 25(OH)D3 and BMD, e.g. Garnero et al. in the
OFELY (Os de Femmes de Lyon) study [30] and others
[11,12,31,32] after adjusting for age.
The observed mean level of PTH ranged in our study
from 34.6 ± 10.9 pg/ml to 40.8 ± 23.3 pg/ml and is simi-
lar to the mean values found of other authors, describing
the mean as 47.9 ± 30.4 ng/ml [26].
Potentially, PTH can exert anabolic and catabolic effects
on osteoblasts by initiating different signalling cascades
[33]. To date, three receptors for PTH/PTHrP are known
on osteoblasts (PTH1R-PTH3R) [34] inducing formation
of cyclic 3’.5’-adenosine monophosphatase (cAMP) by ac-
tivating the adenylate cyclase through stimulatory G-alphaFigure 2 PTH time course.proteins coupled to the receptor [33]. Studies in vitro and
in vivo have shown that the N-terminal 1-34 synthetic
fragment of the 84 amino acids of PTH mediates full PTH
activity [35], eliciting a cAMP response and stimulation of
bone formation [36]. Thus we propose activation of the
bone anabolic effects of PTH especially in the first period
after fracture, when most important stabilization pro-
cesses occur.
In recent literature significant negative correlations
between 25(OH)D3 and PTH have been described [22].
These findings support concur with the results of our
study, where an increase of PTH in first week after
fracture healing is accompanied by a slight decrease of
25(OH)D3.
One lack of our study is of course a missing control
group with matching demographics without fractures,
since especially 25(OH)D3 levels are dependent on mul-
tiple effects like oral supply or exposure to the sun. We
had to accept this problem in our study design, as we
rarely see patients without fractures in our trauma
department.
Conclusions
Herewith the time course of 25(OH)D3 and PTH during
fracture healing of normal and low BMD level bone have
been examined in humans in this setting for the first
time providing biological insights into fracture healing in
metaphyseal bones on a molecular. There were no sig-
nificant differences between normal and low BMD level
patients. Further studies are necessary to obtain a more
detailed insight into fracture healing in order to provide
reliable decision criteria for therapy and monitoring of
fracture healing.
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